BZH Beazer Homes USA Inc.

Beazer Homes Announces Early Results of Tender Offers for 5.75% Senior Notes Due 2019 and 7.25% Senior Notes Due 2023

Beazer Homes USA, Inc. (NYSE: BZH) (the “Company”) announced today the early results of its previously announced cash tender offers for up to $225 million of its 5.25% Senior Notes due 2019 (the “2019 Notes”) and up to $175 million of its 7.25% Senior Notes due 2023 (the “2023 Notes” and together with the 2019 Notes, the “Notes”), upon the terms and conditions included in the Offer to Purchase, dated September 25, 2017 (the “Offer to Purchase”).

The aggregate principal amount of Notes of each series that were validly tendered and not validly withdrawn as of 5:00 p.m., New York City time, on October 6, 2017 (the “Early Tender Deadline”), and the aggregate principal amount of each series of Notes that are expected to be accepted for purchase by the Company on October 10, 2017 (the “Early Settlement Date”), subject to the satisfaction or waiver of certain conditions to the tender offers set forth in the Offer to Purchase are specified in the table below.

           
Principal Amount
Expected to be
Outstanding Accepted for
Aggregate Maximum Principal Purchase on Total
Principal Tender Amount Early Settlement Consideration
Security CUSIP Amount Amount Tendered Date

(1)(2)

5.75% Senior Notes due 2019 07556QBH7 $321,393,000 $225,000,000 $312,978,000 $225,000,000 $238,500,000
7.25% Senior Notes due 2023 07556QBD6 $199,834,000 $175,000,000 $183,989,000 $175,000,000 $184,231,250
 
(1) Excludes Accrued Interest, which will be paid by the Company.
(2) Includes the Early Tender Payment of $30.00 per $1,000 principal amount of Notes.
 

The tender offers are subject to the satisfaction or waiver of certain conditions as described in the Offer to Purchase, including (1) the receipt of at least $400 million in gross proceeds from one or more offerings of senior notes on terms reasonably acceptable to the Company, and (2) certain general conditions, in each case as described in more detail in the Offer to Purchase. If any of the conditions are not satisfied, the Company may terminate the tender offers and return tendered Notes, may waive unsatisfied conditions and accept for payment and purchase all validly tendered Notes, may extend the tender offers or may otherwise amend the tender offers.

Subject to the terms and conditions of the tender offer being satisfied or waived, holders who validly tendered and did not withdraw Notes prior to the Early Tender Deadline will, if their Notes are accepted for purchase, receive the “Total Consideration” equal to $1,060 per $1,000 principal amount of 2019 Notes and $1,052.75 per $1,000 principal amount of 2023 Notes. In addition to the Total Consideration, holders will receive accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest preceding the Early Settlement Date to, but not including, the Early Settlement Date. The Early Settlement Date is expected to be October 10, 2017. The Withdrawal Deadline has passed. Accordingly, any validly tendered notes may no longer be withdrawn or revoked.

As the aggregate consideration to be paid by the Company in respect of each series of Notes that have been tendered would exceed the applicable Maximum Tender Amount, acceptance for tenders of each series of Notes has been prorated such that (i) of the $312,978,000 aggregate principal amount of the 2019 Notes that were tendered as of the Early Tender Deadline, only $225,000,000 aggregate principal amount are expected to be accepted for purchase on the Early Settlement Date and (ii) of the $183,989,000 aggregate principal amount of the 2023 Notes that were tendered as of the Early Tender Deadline, only $175,000,000 aggregate principal amount are expected to be accepted for purchase on the Early Settlement Date.

Because the tender offers have been fully subscribed as of the Early Tender Deadline, no Notes tendered after the Early Tender Deadline will be accepted for purchase in the tender offers. Any Notes tendered after the Early Tender Deadline, together with any Notes tendered at or prior to the Early Tender Deadline but not accepted for purchase by the Company, including Notes not accepted because of proration, will be returned to the holders thereof.

The tender offers will expire at 12:00 midnight, New York City time, at the end of the day on October 23, 2017, unless extended or earlier terminated by the Company (such time and date, as the same may be extended or earlier terminated, the “Expiration Time”).

The complete terms and conditions of the tender offers are set forth in the Offer to Purchase and the Letter of Transmittal that have been sent to holders of the Notes. Holders are urged to read the Offer to Purchase and the Letter of Transmittal carefully.

The Company has engaged Credit Suisse Securities (USA) LLC to act as Dealer Manager for the tender offers. Persons with questions regarding the tender offers should contact Credit Suisse Securities (USA) LLC toll-free at (800) 820-1653 or collect at (212) 325-2476. Requests for documents should be directed to D.F. King & Co., Inc., the Tender and Information Agent for the tender offers, at (212) 269-5550 (for banks and brokers) or (866) 406-2285 (for noteholders).

This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to purchase with respect to any of the Notes. The tender offers are being made pursuant to the tender offer documents, including the Offer to Purchase that the Company is distributing to holders of the Notes. The tender offers are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws of such jurisdiction. None of the Company, the Dealer Manager, the Tender and Information Agent or their respective affiliates is making any recommendation as to whether or not holders should tender all or any portion of their Notes in the tender offers.

About Beazer Homes USA, Inc.

Headquartered in Atlanta, Beazer Homes is one of the country’s 10 largest single-family homebuilders. The Company’s homes meet or exceed the benchmark for energy-efficient home construction as established by ENERGY STAR® and are designed with Choice Plans to meet the personal preferences and lifestyles of its buyers. In addition, the Company is committed to providing a range of preferred lender choices to facilitate transparent competition between lenders and enhanced customer service. The Company offers homes in Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland, Nevada, North Carolina, South Carolina, Tennessee, Texas and Virginia. Beazer Homes is listed on the New York Stock Exchange under the ticker symbol “BZH.”

EN
06/10/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beazer Homes USA Inc.

Moody's Ratings downgrades Beazer Homes's CFR to B2; stable outlook

Moody's Ratings (Moody's) downgraded Beazer Homes USA, Inc.'s (Beazer) corporate family rating (CFR) to B2 from B1, its probability of default rating (PDR) to B2-PD from B1-PD, and the ratings on the company's senior unsecured notes to B2 from B1. We also changed Beazer's Speculative Grade Liquidity...

Beazer Homes USA, Inc. - December 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Beazer Homes USA, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Beazer Homes USA, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 15 September 2025 in which we reassessed the appropriateness of the ratings in the c...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch